art news

02/11/2011
ART reports that its second-generation bioresorbable stent promotes vessel lumen enlargement
The ideal bioresorbable stent would be one that is biocompatible and dismantles in a timely fashion.

PARIS, Nov. 2, 2011—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months followup.
In addition, acute safety data are excellent: there have been more than 250 MACE free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

See complete article

18/05/2011
ART to disclose for the first time the novel design and new data
“We will debunk the myth that polymer based stents are not optimal as a bioresorbable scaffold

PARIS, May 17, 2011—Arterial Remodeling Technologies (“ART”) announced today that details of the state-of-the-art design of its potentially disruptive polymer-based bioresorbable stent platform will be revealed, for the first time, at EuroPCR 2011 from the podium tomorrow (Wednesday, May 18). The disclosure will be presented by Antoine LaFont, M.D., Ph.D., Professor of Medicine, Head Interventional Cardiology Department, Georges Pompidou Hospital (Paris); and, Past Chairman, Interventional Cardiology Group, European Society of Cardiology (ESC). Dr. LaFont is a co-founder of
ART.

See complete article

07/12/2010
Arterial Remodeling Technologies (“ART”) discloses new data for its breakthrough bioresorbable stent
Data presented at 2010 “Innovations in Cardiovascular Interventions” (ICI), Tel-Aviv, Israel

PARIS, Dec. 7, 2010—Arterial Remodeling Technologies (“ART”) disclosed today new data related to its bioresorbable stent platform—additional data that further validates the Company’s innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent. The new data show that the ART stent scaffold can be overinflated by more than 25% without cracking or crazing, and is thus designed to avoid the serious problem of malapposition associated with other bioresorbable stents that was documented at TCT 2010.

See complete article

21/09/2010
Arterial Remodeling Technologies raises $8.5 million in new venture financing round
“Our fully resorbable coronary stents is designed to promote natural remodeling”

PARIS, Sept. 21, 2010—Arterial Remodeling Technologies (“ART”) announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.

See complete article

14/09/2010
CEO of Arterial Remodeling Technologies (“ART”) will update the industry today on the state of
bioresorbable stents at the annual meeting of the European Society of Biomaterials (ESB)

PARIS, Sept. 13, 2010—Arterial Remodeling Technologies (“ART”) announced today that its CEO, Machiel van der Leest, has been invited to present an update on the state of bioresorbable stents during today’s 23rd annual meeting of the ‘ESB’ (European Society of Biomaterials), at Tampere (Finland) University of Technology.

See complete article

20/05/2010
ART discloses data from in vivo study that its stent’s biodegradability is quantifiable while preser
We continue to demonstrate that ART is the leading innovator

PARIS, May 20, 2010—Arterial Remodeling Technologies (“ART”) disclosed today the results of an in vivo study of 48 porcine arteries implanted with its biodegradable stent. The study demonstrated that (1) the ART stent’s biodegradation is measurable and begins at the first day of implant; (2) that the ART stent retains high radial strength, thus maintaining its structural integrity during biodegradation; and, (3) that the ART stent causes virtually no inflammation of the blood vessel wall.

See complete article

01/02/2010
Arterial Remodeling Technologies receives ISO 13485 certification
Certification comes on the heels of data published in EuroIntervention Journal special supplement

ISO 13485 is an internationally recognized medical device Quality Management System (QMS) standard developed by the International Organization for Standardization (ISO). To be certified to the standard, companies must implement a medical device QMS ensuring that steps have been taken to identify, manage and minimize the risks involved with the manufacturing and use of its medical devices. Certification to ISO 13485 reinforces through an independent third-party that ART operates its medical device QMS in accordance with the recognized standard.

See complete article

04/01/2010
ART reports its bioresorbable stent platform restores the remodeling capacity of arterial walls
Data published in EuroIntervention Journal special supplement

Arterial Remodeling Technologies ("ART") announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform-data that validates the Company's approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent without altering healing by drug elution from the stent platform.

See complete article

04/11/2008
Chief Executive Officer
Paris, November 2008

Arterial Remodeling Technologies (“ART”) announced today that it has appointed Machiel Van Der Leest as its Chief Executive Officer, effective immediately.
Most recently,Van Der Leest was ART’s Chief Operating Officer since March 2008. Prior to joining ART, he was Director of R&D and Regulatory Affairs since May 2003 at Minvasys.

Prior to Minvasys,Van Der Leest was Director of R&D for Cathnet-Science (Nycomed Amersham Medical Systems, or “NAMS”, until July 2000) from Sept. 1999 through May 2003.
He is trilingual (English, French, Dutch) and received a MSc degree in Industrial Design Engineering from the Technical Univ. Delft, Netherlands, in 1996.

E-mail : mvanderleest@art-stent.com

16/07/2008
ART's Article Published in VIVO
Published July 6, 2008

Many industry executives believe bioabsorbable devices may be the next big thing in coronary stents after drug-eluting stents. Most bioabsorbable stent companies are hedging their bets, combining drug elution with stents that disappear. Not ART, who's betting that natural healing beats drug therapy.

See complete article

Website : www.windhover.com/article

E-mail : dcassak@windhover.com

Author : David Cassak

09/06/2008
Interview of Dr. Lafont
Vanishing Stents - Part 2

What if there were a stent that could promote natural remodeling of an injured artery after angioplasty, and then just disappear? "Just three years ago bioresorbable stents seemed to be more of a nice to have than a need to have.
After all, drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. Johnson & Johnson and Boston Scientific had the clear lead in introducing Cypher and Taxus, respectively, to the interventional community, with Medtronic, Guidant, and Abbott Laboratories bringing up the rear. Then in September 2006 at the World Congress of Cardiology meeting...DES were linked to a four-letter word delivering a new danger corporate executives once again began asking a question they thought they had answered: why deploy a permanent implant on a short-term mission of clearing a coronary artery?" (Source: 'Bioabsorbable Stents', Start-Up, January 2007) In part two of “Vanishing Stents”, we again consider Paris-based ARTERIAL REMODELING TECHNOLOGIES ("ART"). ART's stent is designed to provide the requisite initial acute mechanical scaffolding, but, as it dismantles due to bioresorbability, the possibility of arterial remodeling returns to the artery. Our expert is Antoine Lafont, MD, PhD, Professor of Medicine at the University of Paris; Head of Interventional Cardiology at Georges Pompidou Hospital in Paris; and, Chairman of the Interventional Cardiology Group of the European Society of Cardiology (ESC). Dr. Lafont is a co-founder of ART.

See the interview